AzTrials
AzTrials

HypertensionSCALESAIAHTNNCT05002322

Expanding Health Systems Research to Optimize Hypertension Care Cascade in HIV-Infected Individuals in Mozambique

A study testing Systems Analysis and Improvement Approach in people with Hypertension, run by Eduardo Mondlane University at 6 sites in Mozambique.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Undiagnosed and untreated hypertension is a main driver of cardiovascular disease, affecting disproportionately low and middle-income countries, where guidelines to screen and manage hypertension are poorly used. More than 13% of Mozambique adults are infected with HIV, and over 900,000 are on anti-retroviral therapy. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Hypertension
What is being tested?
Systems Analysis and Improvement Approach
Could I receive a placebo?
No, everyone receives an active treatment
How many people
18 participants
Where
6 sitesMozambique
Study dates
14 Feb 2023to 31 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Primary care facility with ongoing cohort of ART patients (minimum 800 patients)

Who cannot join

  • Health facility unaccessible during part of the year

Trial locations and contacts

6 sites in 1 country.

6 sites in 1 country

Mozambique6 sites
  • Centro de Saude da Ponta do Ouro

    Bela Vista, Maputo Province

  • Centro de Saude de Matutuine

    Bela Vista, Maputo Province

  • Centro de Saude de Salamanga

    Bela Vista, Maputo Province

  • Centro de Saúde de Magude

    Magude, Maputo Province

  • Centro de Saúde de Motaze

    Magude, Maputo Province

  • Centro de Saúde de Chichuco

    Magude

Other trials in Mozambique

About this study

Official title: Scaling Out and Scaling Up the Systems Analysis and Improvement Approach to Optimize the Hypertension Diagnosis and Care Cascade for HIV-infected Individuals

Undiagnosed and untreated hypertension is a main driver of cardiovascular disease, affecting disproportionately low and middle-income countries, where guidelines to screen and manage hypertension are poorly used. More than 13% of Mozambique adults are infected with HIV, and over 900,000 are on anti-retroviral therapy. HIV clinics are the only services within primary care providing continued care, and can be used to standardize and scale the hypertension care cascade. Hypertension affects 40% of Mozambican adults, and thus HIV and HTN often coexist in the same person.

The investigators propose to use low-cost tools that improve service performance, promote routine hypertension diagnosis and management, and ameliorate flow through the hypertension cascade, thus improving patients outcomes. Building on a current project some districts of two provinces of central Mozambique, the investigators will establish scientific evidence on the effectiveness of a tool that uses cycles of evaluation and improvement of health system, to address the hypertension care cascade in HIV-infected people. The investigators will strengthen the framework currently in use (based on nurses) setting a novel modality delivered by district health supervisors, and will expand the geographic study area by adding 6 districts of one additional province in southern Mozambique (Maputo Province), to create a foundation for national scale-up.

The Project planning phase (two years) will develop a multi-sectoral partnership of key stakeholders, establish national technical working groups with the participation of the provinces, and identify key facilitators and barriers that could affect uptake of the results, integration of high blood pressure and HIV services, scale-up to the entire country, and sustainability of the tested framework. Additionally, the investigators will i) conduct a six-months pilot study to assess feasibility and acceptability of the district supervisor-led intervention in one primary care facility; and, ii) redesign tools and standard operating procedures, as necessary. During the implementation phase (last three years) the investigators will deploy the district-based dissemination and implementation randomized trial in 18 health facilities - using an intervention that involves assessment, effectiveness evaluation, promotion of local uptake, implementation and maintenance - and determine the costs of the hypertension care cascade optimization, by estimating the total incremental costs.

Read the detailed description

In Mozambique HIV prevalence is over 13% and hypertension (HTN) affects 40% of adults. HIV and HTN comorbidity is increasing with the aging of HIV-infected population and expansion of antiretroviral therapy (ART), but guideline application for HTN screening and management remains low and uneven. Around 14% of adults are aware of their HTN status and only 3% of those with HTN have their condition controlled. The HIV treatment platform is the only broadly implemented chronic care service and provides an opportunity to standardize and scale HTN screening and management.

Systems-level implementation strategies may reduce drop-offs along the HTN cascade, improve service quality, and maximize availability of efficacious HTN medicines. Systems engineering tools can identify drivers of inefficiency, support locally informed provider decision-making to prioritize solutions, and improve integration of services to reduce inefficiencies in complex, multi-step health services using simple, low cost, iterative adaptations in service delivery design. The participation of frontline staff and senior management champions in this process improves patient outcomes.

The investigators aim to describe HTN care cascade at the health facility level and use it as the entry point for systems optimization of HIV services, using cascade analysis and associated systems engineering tools. In central Mozambique a Systems Analysis and Improvement Approach (SAIA) identified HTN cascade steps for PLHIV, developed a HTN Cascade Analysis Tool (HCAT), mapped data sources, and developed a registry to populate the HCAT and capture study outcomes from outpatient registries and patient charts (SAIA-HTN). Building on this, our project will 'scale out' through the novel modality of delivery by district health supervisors, and 'scale up' by expanding to six districts in one additional province (SCALE SAIA-HTN). It also aims at developing a dissemination and implementation model to serve as a foundation for national scaling.

Projects Aims:

  1. To develop a multi-sectoral partnership of key stakeholders and establish HTN technical working groups at the national level and participating provinces;
  2. To identify key facilitators and barriers that could affect the adoption, integration, scale-up and sustainment of the SAIA-HTN implementation strategy;
  3. To conduct a pilot study to assess feasibility and acceptability of the district MOH supervisor-led SAIA-HTN intervention over six months in one primary care facility (to redesign tools and standard operating procedures as necessary);
  4. Develop a district-based dissemination and implementation of SAIA-HTN (SCALE SAIA-HTN) using the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) model to evaluate the program: a. Determine the proportion of health facilities and population in the six districts reached, and identification of sub-groups not reached (target: 33% of facilities and 80% HIV+ adults reached); b.Assess the intervention effect on HTN process measures (BP screening, HTN diagnosis, HTN medication initiation, maintenance on HTN treatment), and HTN treatment effectiveness (HTN control, HIV viral load suppression); c.Determine the proportion of districts and facilities adopting the intervention (target: 95%), and explore the determinants of adoption identified using the Organizational Readiness for Implementing Change (ORIC); d.Determine core elements of the scaled SAIA-HTN implementation process and describe drivers of success/failure using the Consolidated Framework for Implementation Research (CFIR); e.Calculate the proportion of districts sustaining the intervention 9 and 18 months post-introduction (target: >90% at 9 months, >80% at 18 months).
  5. Determine the costs of SCALE SAIA-HTN for care cascade optimization, including total incremental and unit costs of integrating HTN diagnosis and management into HIV care.

Methods: The investigators will use the SAIA strategy to visualize and quantify interconnected service delivery steps, informed by previous SAIA research, epidemiologic research on HTN, and ongoing SAIA-HTN research to optimize HTN screening, care and treatment for PLHIV in central Mozambique (to evaluate SAIA-HTN's effectiveness on systems' and patient-level health outcomes for PLHIV).

Study Plan: The investigators will use multiple novel implementation science methods to understand and explain what influences implementation outcomes, including i) the CFIR to identify barriers and facilitators (determinants) to implementation, ii) the ORIC scale to assesses readiness for change as an organizational-level determinant of adoption, and iii) the RE-AIM evaluative Framework, which measures the active ingredients for public health impact (Reach, Effectiveness, Adoption, Implementation and Maintenance).

Planning phase: The investigators will mobilize a multi-sectoral stakeholder partnership, conduct a needs assessment (to evaluate facilitators and barriers that could affect adoption, integration, scale-up and sustainment of SCALE SAIA-HTN in the two provinces), and pilot the intervention's feasibility and acceptability over six months in one clinics (to refine implementation procedures for follow-on scaling out and scaling up).Implementation phase: 'scale out' SAIA-HTN to test a novel delivery modality (using district supervisors), 'scale up' to cover six districts in Maputo province, and evaluate its impact on cascade performance and patient outcomes. The investigators will randomly allocate health facilities from the six districts in Maputo Province into three implementation waves, staggered by nine months (27 months total).

The SAIA-HTN implementation strategy uses an iterative, five-step process applied at the facility level to give clinic staff and managers a systems view of cascade performance, identify priority areas for improvement, discern modifiable solutions, and test workflow modifications.

SCALE SAIA-HTN will test integration and scale up of SAIA-HTN through routine management systems relying on district Ministry of Health (MOH) supervisors as the disseminating agents (rather than research nurses), in three facilities per district during a nine-month intensive phase (mentored by study assistants), and subsequent sustainment phase (led independently by district MOH supervisors). Based on trial results, the investigators will model out the costs and potential benefits on HTN management for PLHIV given different scale-up scenarios nationwide. The trial will culminate in the development and dissemination of the SCALE SAIA-HTN package, summarizing trial results and providing implementation and cost guidance to inform policy development and support national scale-up through routine management structures.

Study design: phased-in (stepped wedge) with random assignment of two districts to each of the three nine-month intervention waves, to reach six districts in Maputo Province by the end of the trial.

Study Setting: Maputo Province (population of >1.5 million inhabitants; >98% of formal health services offered through public sector clinics). Health facilities with highest numbers of active HIV+ patients on ART will be enrolled.

Study Team: This project brings together a diverse and uniquely qualified team of cardiovascular, HIV, community surveys, health systems, and implementation scientists.

Procedures Stakeholders meetings: to create a multi-sectoral partnership of key stakeholders and establish HTN technical working groups (TWG) at the national level and with participating provinces.

Stakeholder field visits to SAIA-HTN trial in central Mozambique: for key personnel and district MOH supervisors from the pilot facility.

Orientation meetings/workshops: for introducing SCALE SAIA-HTN, the implementation approach, and evaluation design to study investigators, provincial MOH managers, and district MOH supervisors in each province, who will review and agree on study procedures, and clinical and organizational skills-building approaches. Throughout the two phases of the project the TWG will inform on mediators and mechanisms of action, scale-up and sustainment efforts, and ensure responsiveness to local needs; at end of the planning phase, the TWG will review findings, discuss necessary adaptations and refine SCALE SAIA-HTN for the implementation phase.

Standardized readiness assessments: in the six first wave health facilities to assess structural and organizational readiness to deliver HTN services (ORIC measures, staffing levels, attributes and training, availability of essential commodities, equipment and supplies, and infrastructure) and repeated for subsequent waves prior to launching intensive implementation phases.

Pilot study: Outpatient staff managing HIV/CVD care and district MOH supervisors will participate in orientation training for the feasibility and acceptability of the SCALE SAIA-HTN intervention, which will be carried out over six months in one primary care facility. Tools and standard operating procedures will be redesigned as necessary for the implementation phase. Facility-based HTN screening will be carried out by nurses at entry into the pilot facility; all hypertensive (new and existing) patients will be recruited, with the support of district supervisors and study teams. Feasibility and acceptability will include i) measurement of intervention fidelity, reach and exposure, and adoption; ii) knowledge and competency questionnaire to health personnel. Follow-up visits to both monitor and support implementation will be carried out twice in the first month, and monthly thereafter. Additional data will be collected by: focus group discussion (FGD) with key staff to assess acceptability of content and delivery of the intervention; questionnaire to participating staff pre and post-intervention; key informant interviews with the district supervisors, facility managers and frontline staff.

Evaluate programs' Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) Reach: determine the number, proportion/representativeness of individuals reached by interventions; use study reports to estimate the proportion of facilities in the six districts reached by SCALE SAIA-HTN (target: 33%); determine the number and proportion of HIV-infected adults with HTN reached (target: 80%).

Effectiveness: HTN treatment effectiveness (primary effectiveness outcome: HTN control, Secondary outcomes: HIV viral load suppression, proportion of HIV- infected patients screened for HTN in outpatient services, HTN diagnosis, HTN prescription of eligible patients, >90% patient adherence to HTN treatment).

Adoption: ORIC assessment scale (target of 95%) used to six frontline staff working across the HIV-HTN cascade and facility leadership in each clinic (n=108), and two supervisors (NCD and HIV) from each district (n=12) to describe determinants of adoption.

Implementation: Tools at CFIR website will be adapted to gather data via interviews and FGDs with facility and district staff (qualitative), intervention meeting minutes (qualitative), and annual quantitative questionnaires to quantify facility structural determinants of implementation of HTN management guidelines.

Maintenance. Proportion of districts sustaining the intervention as designed 18 months for wave I and 9 months for wave II post-introduction (target: >90% at 9 months, >80% at 18 months). In-depth interviews and FGDs to probe district/facility perspectives on determinants of sustainment

Determination of the costs of SCALE SAIA-HTN for care cascade optimization: total incremental and unit costs of integrating HTN diagnosis and management into HIV care. For cost estimation activity-based cost menus will identify start up and recurrent activities, and measure resource use and costs from design through implementation. Cost metrics will include the total incremental costs and average unit costs.

Conditions
Hypertension
Being tested
Systems Analysis and Improvement Approach
Keywords
Systems analysis and improvement approach (SAIA),, Hypertension, CFIR, ORIC, Process mapping, Cascade analysis, Continuous quality improvement, Implementation science, Systems engineering, HIV
Medical subject headings
Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Systems Analysis and Improvement ApproachOther

    Intensive phase: district MOH supervisors receive a one-week training on SAIA-HTN. The nine-month intervention wave will be mentored by INS study personnel who will accompany and support district MOH supervisors as they implement at the facility level. Over the first week of each iterative cycle, facility teams populate and interpret the HCAT, develop process maps, define one to two micro-interventions and indicators to monitor these modifications. Facility teams receive two mentorship visits by district supervisors and study personnel for the first month, followed by monthly visits throughout intensive implementation.

    Sustainment phase (depending on implementation wave allocation): district supervisors will independently lead implementation, with financial support for travel to clinics and to hold meetings, but without intensive support from study personnel.

Study groups in NCT05002322
Study groupRoleWhat they receive
intervention health facilitiesExperimentalHealth facilities implement the optimization of the cascade under research team support and continuous supervision.
Receives: Other: Systems Analysis and Improvement Approach
ControlNo interventionHealth facilities prior to intensive phase receive standard supervision without research team support

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Controlled hypertension

    The proportion of PLHIV with controlled hypertension a minimum of 75 days after starting treatment, among those who were diagnosed with hypertension, prescribed hypertension treatment, and who picked up their medications

    Measured: Per Phase: up 2 months for Baseline Phase, up to 9 months for Intensive Implementation Phase, up to 18 months for Wave 1 or up to 9 months for Wave 2 Sustainment Phase.

Secondary outcomes (5)
  1. Blood pressure screening

    The proportion of HIV consultations in which a PLHIV was screened for hypertension

    Measured: Per Phase: up 2 months for Baseline Phase, up to 9 months for Intensive Implementation Phase, up to 18 months for Wave 1 or up to 9 months for Wave 2 Sustainment Phase

  2. Hypertension diagnosis

    The proportion of HTN screenings, in which a PLHIV was newly diagnosed with hypertension or had an existing hypertension diagnosis re-confirmed

    Measured: Per Phase: up 2 months for Baseline Phase, up to 9 months for Intensive Implementation Phase, up to 18 months for Wave 1 or up to 9 months for Wave 2 Sustainment Phase

  3. New hypertension diagnosis

    The proportion of HTN screenings, in which a PLHIV was newly diagnosed with hypertension

    Measured: Per Phase: up 2 months for Baseline Phase, up to 9 months for Intensive Implementation Phase, up to 18 months for Wave 1 or up to 9 months for Wave 2 Sustainment Phase

  4. Hypertension treatment prescription

    The proportion of PLHIV who received a prescription for hypertension treatment medication among those who were diagnosed with hypertension (i.e. medication-eligible)

    Measured: Per Phase: up 2 months for Baseline Phase, up to 9 months for Intensive Implementation Phase, up to 18 months for Wave 1 or up to 9 months for Wave 2 Sustainment Phase

  5. Hypertension medication pick-up

    The proportion of PLHIV who pick up their hypertension medications among those who were prescribed hypertension treatment

    Measured: Per Phase: up 2 months for Baseline Phase, up to 9 months for Intensive Implementation Phase, up to 18 months for Wave 1 or up to 9 months for Wave 2 Sustainment Phase

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Aug 2021
  2. Study start14 Feb 2023
  3. Primary completion31 Dec 2025
  4. Study completion31 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Sequential
Model description
phased-in (stepped wedge) design with random assignment of two districts to each of the three nine-month intervention waves, to reach six districts in Maputo Province by the end of the trial
Masking
None (open label)
Enrolment
18 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05002322
Sponsor's protocol ID
SCALESAIA2020
Other IDs
4UH3HL156390-03
Acronym
SCALESAIAHTN
Status last verified
Feb 2026
First submitted
3 May 2021
Last updated
27 Feb 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014 Aug;2(8):634-47. doi: 10.1016/S2213-8587(14)70102-0. Epub 2014 May 16.

    PubMed 24842598
  • Kengne AP, Ntyintyane LM, Mayosi BM. A systematic overview of prospective cohort studies of cardiovascular disease in sub-Saharan Africa. Cardiovasc J Afr. 2012 Mar;23(2):103-12. doi: 10.5830/CVJA-2011-042. Epub 2011 Sep 7.

    PubMed 21901226
  • Ibrahim MM, Damasceno A. Hypertension in developing countries. Lancet. 2012 Aug 11;380(9841):611-9. doi: 10.1016/S0140-6736(12)60861-7.

    PubMed 22883510
  • van de Vijver S, Akinyi H, Oti S, Olajide A, Agyemang C, Aboderin I, Kyobutungi C. Status report on hypertension in Africa--consultative review for the 6th Session of the African Union Conference of Ministers of Health on NCD's. Pan Afr Med J. 2013 Oct 5;16:38. doi: 10.11604/pamj.2013.16.38.3100. eCollection 2013.

    PubMed 24570798
  • Ministerio da Saude. Relatorio Anual 2017 HIV. Maputo, Mocambique: Ministerio da Saude; 2014.

  • Jessen N, Damasceno A, Silva-Matos C, Tuzine E, Madede T, Mahoque R, Padrao P, Mbofana F, Polonia J, Lunet N. Hypertension in Mozambique: trends between 2005 and 2015. J Hypertens. 2018 Apr;36(4):779-784. doi: 10.1097/HJH.0000000000001618.

    PubMed 29210894
  • Antonello VS, Antonello IC, Grossmann TK, Tovo CV, Pupo BB, Winckler Lde Q. Hypertension--an emerging cardiovascular risk factor in HIV infection. J Am Soc Hypertens. 2015 May;9(5):403-7. doi: 10.1016/j.jash.2015.03.008. Epub 2015 Mar 28.

    PubMed 25979413
  • Lloyd-Sherlock P, Ebrahim S, Grosskurth H. Is hypertension the new HIV epidemic? Int J Epidemiol. 2014 Feb;43(1):8-10. doi: 10.1093/ije/dyu019. Epub 2014 Feb 3. No abstract available.

    PubMed 24491955
  • Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone NF. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb;11(1):20-5. doi: 10.1177/1545109711418361. Epub 2011 Aug 29.

    PubMed 21876213
  • Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, Prins M, Reiss P; AGEhIV Cohort Study Group. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014 Dec 15;59(12):1787-97. doi: 10.1093/cid/ciu701. Epub 2014 Sep 2.

    PubMed 25182245
  • Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP Jr, Klein DB, Towner WJ, Horberg MA, Silverberg MJ. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):39-46. doi: 10.1097/QAI.0000000000001014.

    PubMed 27028501
  • Dzudie A, Rayner B, Ojji D, Schutte AE, Twagirumukiza M, Damasceno A, Ba SA, Kane A, Kramoh E, Anzouan Kacou JB, Onwubere B, Cornick R, Sliwa K, Anisiuba B, Mocumbi AO, Ogola E, Awad M, Nel G, Otieno H, Toure AI, Kingue S, Kengne AP, Perel P, Adler A, Poulter N, Mayosi B; PASCAR Task Force on Hypertension. Roadmap to Achieve 25% Hypertension Control in Africa by 2025. Glob Heart. 2018 Mar;13(1):45-59. doi: 10.1016/j.gheart.2017.06.001. Epub 2017 Oct 16.

    PubMed 29042191
  • Kayima J, Wanyenze RK, Katamba A, Leontsini E, Nuwaha F. Hypertension awareness, treatment and control in Africa: a systematic review. BMC Cardiovasc Disord. 2013 Aug 2;13:54. doi: 10.1186/1471-2261-13-54.

    PubMed 23915151
  • Baekken M, Os I, Sandvik L, Oektedalen O. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens. 2008 Nov;26(11):2126-33. doi: 10.1097/HJH.0b013e32830ef5fb.

    PubMed 18854751
  • Sherer R, Solomon S, Schechter M, Nachega JB, Rockstroh J, Zuniga JM. HIV provider-patient communication regarding cardiovascular risk: results from the AIDS Treatment for Life International Survey. J Int Assoc Provid AIDS Care. 2014 Jul-Aug;13(4):342-5.

    PubMed 25513031

Questions about this trial

What is this clinical trial studying?

A study testing Systems Analysis and Improvement Approach in people with Hypertension, run by Eduardo Mondlane University at 6 sites in Mozambique.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 6 sites in Mozambique. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Controlled hypertension (time frame: Per Phase: up 2 months for Baseline Phase, up to 9 months for Intensive Implementation Phase, up to 18 months for Wave 1 or up to 9 months for Wave 2 Sustainment Phase.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05002322, which also lists 58 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in